| Literature DB >> 29045029 |
Paul N Schwarz1, Anina Buchmann2, Luisa Roller1, Andreas Kulik1, Harald Gross2,3, Wolfgang Wohlleben1,3, Evi Stegmann1,3.
Abstract
Nocardia terpenica IFM 0406 is the producer of the immunosuppressants brasilicardins A-D. Brasilicardin is a promising compound because of its unique mode of action and its higher potency and reduced toxicity compared to today's standard drugs. However, production of brasilicardin is so far hampered as Nocardia terpenica IFM 0406 synthesizes brasilicardin in only low amounts and represents a human pathogen (biosafety level 2 BSL2). In order to achieve a safe and high yield production of brasilicardin A (BraA), the authors heterologously express the brasilicardin gene cluster in the nocardioform actinomycete Amycolatopsis japonicum (A. japonicum::bcaAB01), which is fast growing, genetically accessible and closely related to N. terpenica IFM 0406. In A. japonicum::bcaAB01, four brasilicardin congeners, intermediates of the BraA biosynthesis, are produced. Investigation of the genes flanking the previously defined brasilicardin biosynthetic gene cluster revealed two novel genes (bra0, bra12), which are involved in brasilicardin biosynthesis: bra12 encodes a transcriptional activator of the brasilicardin gene cluster. bra0 codes for a dioxygenase involved in methoxylation of brasilicardin. Based on this finding the authors are able to revise the proposed brasilicardin biosynthesis.Entities:
Keywords: Norcardia terpenica; Pseudonocardia; SARP-like regulator; dioxygenase; terpene
Mesh:
Substances:
Year: 2017 PMID: 29045029 DOI: 10.1002/biot.201700527
Source DB: PubMed Journal: Biotechnol J ISSN: 1860-6768 Impact factor: 4.677